BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XmAb541 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of XmAb541\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06276491-10850@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:XmAb541: Phase 1 readout est. (NCT06276491)
DESCRIPTION:XmAb541\, phase 1\, Ovarian Cancer.\nStudy: Phase 1\, Safety an
 d Tolerability Study of XmAb541 in Advanced Solid Tumors\nEstimated primar
 y completion: December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/xmab541#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06276491
URL:https://assetmemo.bio/drug/xmab541#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07593092-10850@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:XmAb541: Phase 1 readout est. (NCT07593092)
DESCRIPTION:XmAb541\, phase 1\, Ovarian Cancer.\nStudy: Phase 1\, Safety an
 d Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors\nEsti
 mated primary completion: December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xmab541#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07593092
URL:https://assetmemo.bio/drug/xmab541#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
